Drew Ranieri
Stock Analyst at Morgan Stanley
(1.24)
# 3,520
Out of 4,884 analysts
166
Total ratings
44.94%
Success rate
-12.49%
Average return
Main Sectors:
Stocks Rated by Drew Ranieri
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ORGO Organogenesis Holdings | Maintains: Equal-Weight | $4 → $6 | $4.25 | +41.18% | 4 | Mar 5, 2025 | |
| ATEC Alphatec Holdings | Assumes: Equal-Weight | $9.5 → $10 | $10.99 | -9.01% | 10 | Dec 2, 2024 | |
| GMED Globus Medical | Upgrades: Overweight | $83 → $100 | $59.17 | +69.00% | 12 | Dec 2, 2024 | |
| SYK Stryker | Upgrades: Overweight | $370 → $445 | $395.28 | +12.58% | 9 | Dec 2, 2024 | |
| SIBN SI-BONE | Maintains: Overweight | $21 → $19 | $18.47 | +2.87% | 15 | Aug 6, 2024 | |
| IART Integra LifeSciences Holdings | Maintains: Underweight | $24 → $27 | $13.49 | +100.15% | 15 | Jul 15, 2024 | |
| TMCI Treace Medical Concepts | Maintains: Equal-Weight | $5.5 → $8 | $6.18 | +29.45% | 12 | Jul 15, 2024 | |
| STVN Stevanato Group | Maintains: Equal-Weight | $26 → $22 | $24.59 | -10.53% | 16 | Jul 15, 2024 | |
| NPCE NeuroPace | Maintains: Equal-Weight | $9.5 → $8 | $10.39 | -23.00% | 13 | Jul 15, 2024 | |
| OM Outset Medical | Maintains: Equal-Weight | $75 → $83 | $20.90 | +294.74% | 10 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $38 | $20.39 | +86.37% | 9 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $88 → $96 | $76.87 | +24.89% | 10 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $28 → $26 | $12.35 | +110.53% | 8 | May 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $290 → $295 | $176.16 | +67.46% | 2 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $236 → $280 | $119.90 | +133.53% | 5 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $5 | $7.02 | -28.77% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $70 | $31.01 | +125.73% | 4 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $325 → $300 | $544.47 | -44.90% | 6 | Apr 25, 2022 |
Organogenesis Holdings
Mar 5, 2025
Maintains: Equal-Weight
Price Target: $4 → $6
Current: $4.25
Upside: +41.18%
Alphatec Holdings
Dec 2, 2024
Assumes: Equal-Weight
Price Target: $9.5 → $10
Current: $10.99
Upside: -9.01%
Globus Medical
Dec 2, 2024
Upgrades: Overweight
Price Target: $83 → $100
Current: $59.17
Upside: +69.00%
Stryker
Dec 2, 2024
Upgrades: Overweight
Price Target: $370 → $445
Current: $395.28
Upside: +12.58%
SI-BONE
Aug 6, 2024
Maintains: Overweight
Price Target: $21 → $19
Current: $18.47
Upside: +2.87%
Integra LifeSciences Holdings
Jul 15, 2024
Maintains: Underweight
Price Target: $24 → $27
Current: $13.49
Upside: +100.15%
Treace Medical Concepts
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $5.5 → $8
Current: $6.18
Upside: +29.45%
Stevanato Group
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $26 → $22
Current: $24.59
Upside: -10.53%
NeuroPace
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $9.5 → $8
Current: $10.39
Upside: -23.00%
Outset Medical
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $75 → $83
Current: $20.90
Upside: +294.74%
Nov 2, 2023
Maintains: Overweight
Price Target: $42 → $38
Current: $20.39
Upside: +86.37%
May 12, 2023
Maintains: Equal-Weight
Price Target: $88 → $96
Current: $76.87
Upside: +24.89%
May 4, 2023
Maintains: Underweight
Price Target: $28 → $26
Current: $12.35
Upside: +110.53%
Feb 3, 2023
Maintains: Overweight
Price Target: $290 → $295
Current: $176.16
Upside: +67.46%
Jan 6, 2023
Maintains: Equal-Weight
Price Target: $236 → $280
Current: $119.90
Upside: +133.53%
Nov 10, 2022
Maintains: Overweight
Price Target: $11 → $5
Current: $7.02
Upside: -28.77%
Oct 11, 2022
Maintains: Overweight
Price Target: $72 → $70
Current: $31.01
Upside: +125.73%
Apr 25, 2022
Maintains: Equal-Weight
Price Target: $325 → $300
Current: $544.47
Upside: -44.90%